Table 5 Treatment and clinical data at last follow-up
From: Phenotypic characterization of X-linked hypophosphatemia in pediatric Spanish population
Patient | Phosphorus element dose (mg/kg/day) | Vitamin D dose (µg/day) | Nephrocalcinosis |
|---|---|---|---|
I.1 | 38a | 0.50c | No |
I.2 | 40a | 0.50c | No |
II.1 | 86a | 1.20d | Yes |
III.1 | – | – | – |
IV.1 | 83a | 0.60d | No |
IV.2 | 62a | 1.00d | No |
V.1 | – | – | – |
VI.1 | – | – | – |
VII.1 | – | – | No |
VII.2 | – | – | – |
VII.3 | 55b | 0.50c | Yes |
VII.4 | 52b | 0.50c | Yes |
VIII.1 | 90a | 1.50d | Yes |
IX.1 | – | – | – |
X.1 | 40a | 0.25d | No |
XI.1 | 83a | 0.50c | No |
XII.1 | 44b | 0.29d | No |
XIII.1 | 41b | 0.25c | Yes |
XIV.1 | 52a | 1.20d | – |
XV.1 | 41b | 1.00c | No |
XVI.1 | – | – | – |
XVII.1 | 45b | 0.25c | Yes |
XVIII.1 | – | – | – |
XIX.1 | 27b | 0.50c | Yes |
XX.1 | 32a | 0.50c | No |
XXI.1 | 63a | 1.50d | No |
XXII.1 | – | – | – |
XXIII.1 | 65a | 1.10d | No |
XXIV.1 | – | – | – |
XXV.1 | 38a | 1.40c | – |
XXVI.1 | 58b | 0.25c | No |
XXVII.1 | 48b | 0.60d | No |
XXVII.2 | – | – | – |
XXVIII.1 | – | – | – |
XXVIII.2 | – | – | – |
XXIX.1 | – | 0.10d | No |
XXX.1 | – | – | – |
XXX.2 | – | – | Yes |
XXXI.1 | – | – | – |
XXXII.1 | – | – | – |
XXXIII.1 | 49b | 0.75c | No |
XXXIV.1 | – | – | – |
XXXV.1 | – | – | – |
XXXV.2 | – | – | – |
XXXVI.1 | – | – | – |
XXXVII.1 | – | – | – |
XXXVIII.1 | – | – | – |
XXXIX.1 | – | – | – |